Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Net Cash Flow (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Net Cash Flow for 4 consecutive years, with $22.6 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 221.1% to $22.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $180.9 million through Dec 2025, up 3788.72% year-over-year, with the annual reading at $180.9 million for FY2025, 3788.72% up from the prior year.
  • Net Cash Flow hit $22.6 million in Q4 2025 for Taysha Gene Therapies, up from -$15.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $196.2 million in Q2 2025 to a low of -$52.5 million in Q1 2022.
  • Historically, Net Cash Flow has averaged $10.7 million across 4 years, with a median of -$18.5 million in 2023.
  • Biggest YoY gain for Net Cash Flow was 473.27% in 2023; the steepest drop was 138.03% in 2023.
  • Year by year, Net Cash Flow stood at $53.6 million in 2022, then tumbled by 138.03% to -$20.4 million in 2023, then rose by 8.46% to -$18.7 million in 2024, then skyrocketed by 221.1% to $22.6 million in 2025.
  • Business Quant data shows Net Cash Flow for TSHA at $22.6 million in Q4 2025, -$15.4 million in Q3 2025, and $196.2 million in Q2 2025.